Your browser is no longer supported. Please, upgrade your browser.
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.22 Insider Own0.16% Shs Outstand39.28M Perf Week8.40%
Market Cap1.05B Forward P/E- EPS next Y-1.46 Insider Trans-25.73% Shs Float30.87M Perf Month47.45%
Income-48.30M PEG- EPS next Q-0.37 Inst Own81.50% Short Float11.15% Perf Quarter39.31%
Sales4.50M P/S233.16 EPS this Y75.80% Inst Trans-1.00% Short Ratio4.92 Perf Half Y149.77%
Book/sh5.86 P/B4.74 EPS next Y17.50% ROA-25.70% Target Price26.33 Perf Year923.99%
Cash/sh5.28 P/C5.26 EPS next 5Y- ROE-29.90% 52W Range1.50 - 29.30 Perf YTD58.39%
Dividend- P/FCF- EPS past 5Y29.30% ROI-58.50% 52W High-5.29% Beta2.73
Dividend %- Quick Ratio16.60 Sales past 5Y-0.10% Gross Margin- 52W Low1750.00% ATR1.66
Employees127 Current Ratio16.60 Sales Q/Q40.00% Oper. Margin- RSI (14)75.47 Volatility7.49% 7.35%
OptionableYes Debt/Eq0.00 EPS Q/Q51.50% Profit Margin- Rel Volume0.83 Prev Close27.71
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume699.87K Price27.75
Recom2.00 SMA2017.17% SMA5037.93% SMA20093.69% Volume582,670 Change0.14%
Feb-21-20Initiated Cantor Fitzgerald Overweight $8
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Feb-23-21 06:01AM  
Feb-22-21 04:01PM  
Jan-26-21 12:39AM  
Jan-08-21 08:51AM  
Jan-04-21 08:01AM  
Dec-23-20 06:55AM  
Dec-09-20 08:01AM  
Nov-30-20 04:01PM  
Nov-27-20 12:30AM  
Nov-09-20 08:01AM  
Nov-05-20 05:55PM  
Nov-03-20 12:31PM  
Oct-15-20 08:14PM  
Oct-14-20 11:32AM  
Oct-13-20 08:01AM  
Oct-06-20 06:09PM  
Sep-29-20 08:58AM  
Sep-10-20 04:01PM  
Aug-25-20 01:25PM  
Aug-24-20 08:01AM  
Aug-06-20 04:01PM  
Aug-03-20 08:01AM  
Jul-29-20 12:33PM  
Jul-09-20 11:01AM  
Jul-08-20 07:32AM  
Jun-18-20 10:31AM  
Jun-15-20 10:35PM  
Jun-12-20 10:39AM  
Jun-11-20 10:39AM  
Jun-09-20 07:46AM  
Jun-06-20 03:01AM  
May-28-20 03:22PM  
May-25-20 11:30AM  
May-06-20 04:01PM  
Apr-24-20 08:56AM  
Apr-14-20 08:37AM  
Apr-06-20 08:53AM  
Mar-26-20 04:01PM  
Mar-03-20 08:01AM  
Dec-23-19 10:26AM  
Dec-12-19 11:30AM  
Nov-18-19 08:01AM  
Nov-14-19 09:44AM  
Nov-12-19 09:25AM  
Nov-11-19 08:01AM  
Nov-08-19 07:30AM  
Oct-30-19 10:33AM  
Oct-02-19 08:01AM  
Sep-30-19 04:01PM  
Sep-06-19 12:11PM  
Aug-14-19 09:10AM  
Aug-13-19 11:53AM  
Aug-08-19 04:23PM  
Aug-07-19 06:45PM  
Jul-31-19 04:01PM  
Jun-24-19 08:01AM  
Jun-06-19 09:31AM  
Jun-04-19 10:26AM  
Jun-01-19 02:15PM  
May-26-19 05:03PM  
May-14-19 12:36PM  
May-08-19 07:00AM  
May-07-19 06:15PM  
May-02-19 10:32AM  
Apr-06-19 09:30AM  
Apr-02-19 08:00AM  
Apr-01-19 01:00PM  
Mar-20-19 09:30AM  
Mar-13-19 01:19PM  
Mar-08-19 11:04AM  
Mar-07-19 07:44PM  
Feb-22-19 05:50PM  
Feb-20-19 08:25AM  
Feb-14-19 10:45AM  
Feb-13-19 08:36AM  
Feb-11-19 12:26PM  
Feb-08-19 11:45AM  
Feb-05-19 09:20AM  
Feb-04-19 02:35PM  
Jan-29-19 08:30AM  
Jan-23-19 08:30AM  
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wright Richard M.Sr. VP & CCODec 14Option Exercise6.2120,832129,36511,665Dec 16 04:30 PM
Wright Richard M.Sr. VP & CCODec 14Sale18.6120,832387,611208Dec 16 04:30 PM
Young Diane C.SVP, Chief Medical OfficerJun 11Buy4.732,11510,0042,115Jun 12 07:55 AM
Cavanaugh SarahSVP of Corp Affairs & Admin.Jun 10Buy4.831,0505,0721,367Jun 11 07:54 AM
Heath-Chiozzi MargoSVP of Regulatory AffairsJun 09Buy3.001,0003,0051,000Jun 10 07:55 AM
KELER TIBORExecutive VP & CSOJun 09Buy2.995,00014,9547,357Jun 10 07:54 AM
MARINO JAMES JDirectorJun 09Buy3.008,30524,91512,704Jun 10 07:54 AM
Martin Samuel BatesSVP and CFOJun 09Buy3.059,75029,73810,735Jun 10 07:55 AM
Marucci Anthony SPresident & CEOJun 09Buy3.0615,00045,90019,438Jun 10 07:54 AM